Smart multifunctional core–shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model

Nanoscale ◽  
2012 ◽  
Vol 4 (20) ◽  
pp. 6501 ◽  
Author(s):  
HanJie Wang ◽  
Wenya Su ◽  
Sheng Wang ◽  
Xiaomin Wang ◽  
Zhenyu Liao ◽  
...  
Keyword(s):  
Therapeutic Effect ◽  
Tumor Model ◽  
Intracranial Tumor ◽  
Core Shell

scholarly journals Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants

Drug Research ◽  
2019 ◽  
Vol 70 (02/03) ◽  
pp. 86-90
Author(s):  
Alexander N. Stukov ◽  
Vladimir G. Bespalov ◽  
Valerij A. Alexandrov ◽  
Alexander L. Semenov ◽  
Galina S. Kireeva ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Antitumor Effect ◽  
Tumor Model ◽  
Intracranial Tumor ◽  
Therapeutic Activity ◽  
Ehrlich Tumor ◽  
Limited Ability ◽  
Wide Range ◽  
Therapeutic Doses ◽  
Sufficient Concentration

AbstractGemcitabine is quite effective in the treatment of brain tumors, although this drug has a limited ability to overcome the blood-brain barrier (BBB). Aim of study is to assess the therapeutic efficacy of gemcitabine and other drugs with different permeability of BBB in the model of intracranial tumor. The therapeutic activity of gemcitabine, carmustine, cyclophosphamide and cisplatin was studied in mice with intracranially implanted Ehrlich tumor, and also gemcitabine in various doses - with intramuscularly implanted tumor. On intracranial tumor model gemcitabine (25 mg/kg) increased the life span (ILS) by 60−89% (p<0.001), despite the fact that its permeability of the BBB is about 10%. Therapeutic activity of carmustine, cyclophosphamide and cisplatin (ILS were 44, 22 and 11%, respectively) corresponds with the BBB permeability for these drugs (90, 20 and 8%, respectively). On intramuscular tumor model, gemcitabine showed significant antitumor effect at both 25 and 2.5 mg/kg, indicating a wide range of therapeutic doses of this drug. Pronounced therapeutic effect of gemcitabine on intracranial tumor most likely is due to the small but sufficient concentration of the drug that overcomes the BBB.

Effect of pentobarbital on normal brain protection and on the response of 9L rat brain tumor to radiation therapy

1993 ◽  
Vol 79 (4) ◽  
pp. 577-583 ◽  
Author(s):  
Bruce F. Kimler ◽  
Changnian Liu ◽  
Richard G. Evans ◽  
Robert A. Morantz
Keyword(s):  
Radiation Therapy ◽  
Brain Tumor ◽  
Rat Brain ◽  
Tumor Model ◽  
Intracranial Tumor ◽  
Normal Brain ◽  
Animal Survival ◽  
Significant Difference ◽  
Rat Brain Tumor ◽  
Brain Tumor Model

✓ The authors attempted to confirm published reports that pentobarbital protects against radiation-induced damage to normal rat brain, as well as enhances radiotherapeutic efficacy in a rat brain tumor model. They evaluated animal survival in 9L gliosarcoma-burdened rats that received whole-brain radiation therapy (16, 24, 32, or 40 Gy) while under intraperitoneal pentobarbital (60 mg/kg) or intramuscular ketamine (60 mg/kg) sedation. The animals were examined at autopsy to attribute death to either intracranial tumor growth or normal brain toxicity in the absence of discernible tumor. There was no difference between the two anesthesia groups regarding the survival of unirradiated animals. Radiation therapy produced a significant dose-dependent prolongation in animal survival, which was limited by the development of normal tissue toxicity at the higher doses. When compared to ketamine anesthesia, pentobarbital anesthesia appeared to offer some protection (not statistically significant) against early (but not late) toxicity at selected radiation doses. A reduction in the number of deaths from tissue toxicity suggested an increased antitumor effect, but again this was not statistically significant. Only in one case was there even a marginal significant difference (p = 0.045) between overall therapeutic efficacy in rats sedated with pentobarbital versus ketamine. While there may be a radioprotective effect of pentobarbital in rat brains without intracranial tumor, there is no conclusive evidence for either radioprotection or significant improvement of radiotherapeutic efficacy in this 9L rat brain tumor model.

scholarly journals Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines

2000 ◽  
Vol 191 (10) ◽  
pp. 1699-1708 ◽  
Author(s):  
Christoph Klein ◽  
Hansruedi Bueler ◽  
Richard C. Mulligan
Keyword(s):  
Dendritic Cells ◽  
Gene Transfer ◽  
Tumor Cells ◽  
Therapeutic Effect ◽  
Genetically Modified ◽  
Tumor Model ◽  
Immunological Mechanism ◽  
Subcutaneous Tumor ◽  
Gm Csf ◽  
Metastasis Model

We have directly compared the efficacy of two immunotherapeutic strategies for the treatment of cancer: “vaccination” of tumor-bearing mice with genetically modified dendritic cells (DCs), and vaccination with genetically modified tumor cells. Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow–derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model. In contrast, vaccination with granulocyte/macrophage colony-stimulating factor (GM-CSF)–transduced tumor cells, previously shown to induce potent antitumor immunity in standard tumor challenge assays, led to a decreased therapeutic effect in the metastasis model and no effect in the subcutaneous tumor model. Further engineering of DCs to express either GM-CSF, tumor necrosis factor α, or CD40 ligand via retroviral-mediated gene transfer, led to a significantly increased therapeutic effect in the subcutaneous tumor model. The immunological mechanism, as shown for GM-CSF–transduced DCs, involves MAGE-1–specific CD4+ and CD8+ T cells. Expression of GM-CSF by DCs led to enhanced cytotoxic T lymphocyte activity, potentially mediated by increased numbers of DCs in draining lymph nodes. Our results suggest that clinical studies involving the vaccination with genetically modified DCs may be warranted.

CHEMICAL ENHANCEMENT OF RADIATION IN A RAT INTRACRANIAL TUMOR MODEL

1978 ◽  
Vol 37 (5) ◽  
pp. 584
Author(s):  
N. Allen ◽  
N. R. Clendenon ◽  
L. V. Ko ◽  
T. Kobayashi ◽  
M. Kartha
Keyword(s):  
Tumor Model ◽  
Intracranial Tumor ◽  
Chemical Enhancement

scholarly journals Abstract 3707: 2D organoid (2DO) as human tumor model for predicting therapeutic effect of anti-cancer drugs

2019 ◽  
Author(s):  
Shiki Fujino ◽  
Norikatsu Miyoshi ◽  
Kazuhiro Saso ◽  
Masaru Sasaki ◽  
Masayoshi Yasui ◽  
...  
Keyword(s):  
Therapeutic Effect ◽  
Human Tumor ◽  
Tumor Model ◽  
Cancer Drugs ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document